Department of Surgery "Melanoma, Soft Tissues, Head and Neck, Skin Cancers", Istituto Nazionale dei Tumori Fondazione Pascale Napoli 80131 Naples, Italy.
Department of Surgery "Melanoma, Soft Tissues, Head and Neck, Skin Cancers", Istituto Nazionale dei Tumori Fondazione Pascale Napoli 80131 Naples, Italy.
Eur J Surg Oncol. 2014 Jan;40(1):61-6. doi: 10.1016/j.ejso.2013.09.002. Epub 2013 Sep 12.
Electrochemotherapy (ECT) is a novel modality for the treatment of skin nodules and cutaneous or subcutaneous tumors that allows delivery of low and non-permeant drug into cells. The aim of this prospective single-center study was to evaluate ECT efficacy in the local treatment of Classic Kaposi's sarcoma (CKS) skin localization stage I-II sec. Brambilla et al.
Nineteen consecutive patients affected by classic KS were included in this study. All patients underwent blood sampling and concurrent incisional biopsy for histological diagnosis and Kaposi's sarcoma related herpes virus 8 (HHV-8) molecular analysis. ECT treatment of KS cutaneous lesions were performed according to the European Standard Operating Procedures of Electrochemotherapy (ESOPE). The primary endpoint of the study was the evaluation of ECT efficacy in the treatment of KS skin nodules and the assessment of HHV-8 viral load in the peripheral blood following the ECT therapy.
Complete response (CR) was observed in 14 (73.6%) patients after first ECT session, while 3 (15.7%) and 2 (10.5%) out of 19 patients received a second and a third ECT treatment, respectively. Clinical response dragged out the whole follow-up period that ranged between 6 and 31 months with a median of 16 months.
Clinical management of CKS skin localizations still represents a challenging task for surgeons and oncologists. Therefore, according to this and other author's recent experiences, ECT is claimed to become the "new standard of care" as first line treatment strategy for stage I-II CKS patients.
电化疗（ECT）是一种治疗皮肤结节和皮肤或皮下肿瘤的新方法，它可以将低浓度和非渗透性药物递送到细胞内。本前瞻性单中心研究的目的是评估 ECT 在经典卡波西肉瘤（CKS）皮肤定位 I-II 期的局部治疗中的疗效，Brambilla 等人。
本研究纳入了 19 例经典 KS 患者。所有患者均接受了血液采样和同时的切开活检，以进行组织学诊断和卡波西肉瘤相关疱疹病毒 8（HHV-8）分子分析。根据欧洲电化疗标准操作规程（ESOPE）对 KS 皮肤病变进行 ECT 治疗。该研究的主要终点是评估 ECT 治疗 KS 皮肤结节的疗效，并评估 ECT 治疗后外周血中 HHV-8 病毒载量。
19 例患者中，有 14 例（73.6%）在第一次 ECT 后观察到完全缓解（CR），而另外 3 例（15.7%）和 2 例（10.5%）患者分别接受了第二次和第三次 ECT 治疗。临床反应持续了整个随访期，从 6 到 31 个月不等，中位数为 16 个月。
CKS 皮肤定位的临床管理仍然是外科医生和肿瘤学家的一项具有挑战性的任务。因此，根据本研究和其他作者最近的经验，ECT 被认为是 I-II 期 CKS 患者的一线治疗策略，成为“新标准护理”。
